Affiliation:
1. Medical School of Nanjing University
2. Nanjing University
3. nanjing Stomatological Hospital
4. Nanjing Drum Tower Hospital
5. Zhejiang Provincial People's Hospital
Abstract
Abstract
In oral and maxillofacial surgery, flap repair plays an essential role in the quality of postoperative life, but thrombosis is fatal for the survival of the patients. Besides, some postoperative thrombotic diseases, such as pulmonary embolism, also intimidate patients' life. The traditional diagnostic methods are still limited by a large amount of hardware and suffer from inconvenience, delay, and subjectivity. Moreover, the treatments mainly rely upon thrombolytics, such as urokinase (UK) plasminogen activator, which may cause bleeding risk, especially intracerebral hemorrhage. Herein, a kind of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) containing a first near-infrared window (NIR-I) phototheranostic agent Y8 and urokinase plasminogen activator (UK) as the core, and modified with the fibrin-targeting peptide GPRPP on the surface (GPRPP-Y8U@P) were developed for the flap and postoperative thromboembolism treatment. The conjugated molecule Y8 endows GPRPP-Y8U@P with the capacity of NIR-II imaging and excellent photothermal/photodynamic therapeutic effects. In vivo experiments demonstrated that GPRPP-Y8U@P could quickly locate thrombus by NIR-II fluorescence imaging, and semi-quantitative analysis of the embolized blood vessels' paraffin section verified its thrombolytic efficiency. Additionally, the urokinase trapped in the NPs would not result in nonspecific bleeding, tremendously improving physical security and curative effects with minimizing side effects. Overall, the advantages of GPRPP-Y8U@P, such as precise localization of the thrombus, thrombus ablation in the site, and mild side effects, demonstrate the attractiveness of this approach for effective clinical monitoring of thrombus therapy.
Publisher
Research Square Platform LLC